BioArctic AB (BIOA_B) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to BioArctic Q3 Report 2025. For the first part of the conference call, the participants will be in listen-only mode. During the questions and answers session, participants are able to ask questions by dialing pound key 5 on their telephone keypad. Now I will hand the conference over to CEO Gunala Oswald, CFO Anders Martin Loft, and colleagues. Please go ahead. Thank you. Good morning and welcome to Bioartic's presentation for the third quarter of 2025. Bioartic is continuing in a great way in our new era. with yet another quarter where we see more and more patients are getting access to Lekembe. And we are broadening our collaborations, utilizing our brain transporter technology. And we are also broadening our portfolio with new projects and new modalities. And we will talk more about that in today's presentation. Next slide, please. Biotic is listed at nasdaq.com large cap, and this is our disclaimer. Next slide, please. So I'm Gunilla Osvald and I'm the CEO of Bioartic and I will share today's presentation with our CFO Anders Martin Lööf and our Chief R&D Officer Johanna Felting and our Chief Commercial Officer Anna-Kaja Grönblad. Next slide please. So I will start our presentation today by giving some key highlights. We go to next slide please. So before I come into this quarter and the presentation, I just want to give a high level introduction to Biotic, if we have any new listeners today. Bioartic is among the world's leading innovators in precision neurology. And we have two key platforms. The first one is about innovation and generation and development of highly selective antibodies targeting aggregated misfolded forms of toxic proteins. And examples here are, for example, leucanumab, leucanbin and exodanumab. The second one is when we are utilizing ...